Durability of GLP-1-Based Therapies in Obesity: Receptor Adaptation, Tachyphylaxis, and the Therapeutic Ceiling
- 1Miller School of Medicine, University of Miami, 1600 NW 10th Avenue, Miami, FL 33136, USA
- 2Barbara and Donald Zucker School of Medicine at Hofstra/Northwell, 500 Hofstra University, Hempstead, NY 11549, USA
Abstract
Glucagon-like peptide-1 (GLP-1) receptor agonists and related incretin-based therapies have transformed the treatment of type 2 diabetes and obesity. Their dependence on sustained receptor agonism, however, creates an unavoidable longitudinal question: what happens after 5–10 years when a patient has reached a stable plateau at the highest approved or tolerated dose? The answer cannot be inferred from short-term weight loss alone. At the therapeutic ceiling, stable benefit, partial attenuation of appetite or reward effects, progression of the underlying disease, increasing treatment burden, and renewed response to an additional mechanism are all plausible trajectories. This conceptual review argues that tachyphylaxis should be treated as a biologically plausible, testable component of long-term incretin pharmacology. Rapid tachyphylaxis to the gastric-emptying effect of GLP-1 has already been demonstrated. Because chronic weight regulation also depends on sustained signaling through neural and peripheral receptor pathways, partial attenuation of selected effects cannot be assumed absent simply because mean weight loss remains below baseline. Existing trials establish persistent activity for several years, but they were not designed to exclude effect-specific receptor adaptation during long-term stable-dose exposure. Weight-loss physiology also creates powerful competing explanations, including lower energy requirements, adaptive thermogenesis, neuroendocrine defense of body weight, behavioral accommodation, and dose constraints. Withdrawal studies establish treatment dependence, not the absence of on-treatment attenuation. Long-term durability should therefore be assessed across appetite and reward responses, weight maintenance, glycemic and cardiovascular benefit, beta-cell function, gastrointestinal burden, body composition, physical function, and residual disease. This framework is intended to help clinicians recognize a therapeutic ceiling, distinguish its possible mechanisms, and decide when to maintain, combine, switch, or add procedural therapy.
Related
- Glucagon-like peptide-1 receptor agonists and aesthetic surgery: perioperative safety, timing, durability and body composition.
- Patterns of GLP-1 Receptor Agonist Initiation Compared With Other Glucose-Lowering and Anti-Obesity Therapies Among Older Adults
- The Pregnane X Receptor (PXR) contributes to phenotypic plasticity and modulates the sensitivity to targeted therapies in melanoma
- Evaluation of digital binocular therapies for amblyopia after refractive adaptation in treatment-naive children aged 3–13 years: A systematic review and meta-analysis of randomised controlled trials
- Incretin‐Based Therapies as Cardiometabolic Interventions: Outcome Hierarchy, Receptor‐Network Pharmacology and Phenotype‐Based Clinical Positioning
BibTeX
@article{roslin2026durability,
title = {{Durability of GLP-1-Based Therapies in Obesity: Receptor Adaptation, Tachyphylaxis, and the Therapeutic Ceiling}},
author = {Kylie Roslin and Robert Andrews and Brigitte Baella-Olivieri and Mitchell Roslin},
journal = {Journal of Clinical Medicine},
year = {2026},
month = oct,
doi = {10.3390/jcm15218265},
url = {https://www.mdpi.com/2077-0383/15/21/8265},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Durability of GLP-1-Based Therapies in Obesity: Receptor Adaptation, Tachyphylaxis, and the Therapeutic Ceiling
AU - Kylie Roslin
AU - Robert Andrews
AU - Brigitte Baella-Olivieri
AU - Mitchell Roslin
PY - 2026
DA - 2026/10/23
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15218265
UR - https://www.mdpi.com/2077-0383/15/21/8265
AB - Glucagon-like peptide-1 (GLP-1) receptor agonists and related incretin-based therapies have transformed the treatment of type 2 diabetes and obesity. Their dependence on sustained receptor agonism, however, creates an unavoidable longitudinal question: what happens after 5–10 years when a patient has reached a stable plateau at the highest approved or tolerated dose? The answer cannot be inferred from short-term weight loss alone. At the therapeutic ceiling, stable benefit, partial attenuation of appetite or reward effects, progression of the underlying disease, increasing treatment burden, and renewed response to an additional mechanism are all plausible trajectories. This conceptual review argues that tachyphylaxis should be treated as a biologically plausible, testable component of long-term incretin pharmacology. Rapid tachyphylaxis to the gastric-emptying effect of GLP-1 has already been demonstrated. Because chronic weight regulation also depends on sustained signaling through neural and peripheral receptor pathways, partial attenuation of selected effects cannot be assumed absent simply because mean weight loss remains below baseline. Existing trials establish persistent activity for several years, but they were not designed to exclude effect-specific receptor adaptation during long-term stable-dose exposure. Weight-loss physiology also creates powerful competing explanations, including lower energy requirements, adaptive thermogenesis, neuroendocrine defense of body weight, behavioral accommodation, and dose constraints. Withdrawal studies establish treatment dependence, not the absence of on-treatment attenuation. Long-term durability should therefore be assessed across appetite and reward responses, weight maintenance, glycemic and cardiovascular benefit, beta-cell function, gastrointestinal burden, body composition, physical function, and residual disease. This framework is intended to help clinicians recognize a therapeutic ceiling, distinguish its possible mechanisms, and decide when to maintain, combine, switch, or add procedural therapy.
SN - 2077-0383
ER -